literature

HIV mutation literature information.

Drug Resistance to HIV-1 Integrase Inhibitors Among Treatment-Naive Patients in Beijing, China.

PMID: 35300056 2022 Pharmacogenomics and personalized medicine

Result: NGS was more sensitive in detecting low-frequency mutations and a total of 4 mutations were detected by NGS but missed by Sanger sequencing which including M184V (1.31%), K65E (3.72%), E138G (1.21%), and Y188C (1.04%).

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

PMID: 34897227 2022 Journal of acquired immune deficiency syndromes (1999)

Table: Y188C/H

Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia.

PMID: 34622550 2022 HIV medicine

Abstract: Most common mutations were M184V (57.1%), Y188C (25.7%), M46I/L (25.7%) and V82A/M (25.7%).

Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.

PMID: 34064774 2021 Viruses

Result: Seven SDRMS increased in prevalence among NNRTI-experienced persons including K101E, Y181V, Y188C, G190S, P225H, and M230L while four decreased in prevalence including L100I, V106A, K101P, and V181I.

HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.

PMID: 33668946 2021 Pathogens (Basel, Switzerland)

Result: In addition, NGS detected three more mutations in three patients: Y188C, E138A and K103N, at frequencies of 22.96%, 27.38% and 43.68%, respectively.

Result: Within a year, some minority DRMs at frequencies 1%-10% remained unchanged, including: PI-related D30N, M46LI, I54VT and N88D, NRTI-related K65R and NNRTI-related Y188CHL.

High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.

PMID: 34025122 2021 Infectious diseases

Table: Y188C

HIV-1 Drug Resistance and Genetic Transmission Networks Among MSM Failing Antiretroviral Therapy in South China 2014-2019.

PMID: 34377002 2021 Infection and drug resistance

Table: Y188C/H/L

HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.

PMID: 34762770 2021 Journal of the International AIDS Society

Table: Y188C/H

HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.

PMID: 32280691 2020 BioMed research international

Result: K103N (37.55%, 92/245) was the most frequent mutation, followed by G190A/E/K/Q/S/V (28.57%, 70/245), V179I/D/E/T (27.76%, 68/245), V106A/I/M (26.12%, 64/245), Y181C/V (18.78%, 46/245), K101E/H/P (14.69%, 36/245), Y188C/H/L (5.71%, 14/245), L100I (4.08%, 10/245), and M230L (4.08%, 10/245).

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.

PMID: 32180823 2020 Drugs in context

Introduction: Across those clinical isolates (no subtype information was provided), DOR displayed a good antiviral activity with fold changes in EC50<9 against most single mutant viruses, including A98G, E138A/G/K/Q, G190A, K101E/P, K103N/S, L100I, P236L, V106M, V108I, V197D, V90I, Y181C/V, and Y188H/C.

Browser Board

Co-occurred Entities

Filtrator